Folic Acid-Metabolizing Enzymes Regulate the Antitumor Effect of 5-Fluoro-2'-Deoxyuridine in Colorectal Cancer Cell Lines.
In colorectal cancer chemotherapy, the current standard of care includes combination therapy with 5-fluorouracil (5-FU) and leucovorin (LV). However, the factors that determine the LV-mediated enhancement of 5-FU antitumor activity are not fully understood. Therefore, we investigated the roles of thymidine synthase (TYMS), folate receptor 1 (FOLR1), dihydrofolate reductase (DHFR), phosphoribosylglycinamide formyltransferase (GART), methylenetetrahydrofolate dehydrogenase (MTHFD1), and methylenetetrahydrofolate reductase (MTHFR) in LV-mediated enhancement of 5-fluoro-2'-deoxyuridine (FdUrd) cytotoxicity in vitro as a model of 5-FU antitumor activity. These genes were downregulated in DLD-1 and HCT116 human colorectal cancer cells by using small-interfering RNA. Reduced expression of TYMS mRNA significantly increased FdUrd cytotoxicity by 100- and 8.3-fold in DLD-1 and HCT116 cells, respectively. In contrast, reducing the expression of FOLR1, DHFR, GART, MTHFD1, and MTHFR decreased FdUrd cytotoxicity by 2.13- to 12.91-fold in DLD-1 cells and by 3.52- to 10.36-fold in HCT116 cells. These results demonstrate that folate metabolism is important for the efficacy of FdUrd. Overall, the results indicate that it is important to clarify the relationship between folate metabolism-related molecules and 5-FU treatment in order to improve predictions of the effectiveness of 5-FU and LV combination therapy.
Translational Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.
Hiroshi
H
Tsukihara
Translational Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.
Kenta
K
Tsunekuni
Translational Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokushima, Japan.
Teiji
T
Takechi
Int J Cancer. 2015 Mar 1;136(5):E359-86
25220842
Cancer Chemother Pharmacol. 2006 Jun;57(6):835-40
16187112
Ann Oncol. 2009 Oct;20(10):1660-6
19465420
Cancer Res. 1988 Oct 15;48(20):5894-900
3167844
Toxicol In Vitro. 1989;3(4):317-21
20702298
Br J Cancer. 2009 May 19;100(10):1549-57
19384296
Cancer Sci. 2009 May;100(5):903-13
19302291
Clin Cancer Res. 2003 May;9(5):1611-5
12738713
Pharmacogenomics J. 2011 Feb;11(1):61-71
20177420
Br J Cancer. 2004 Jan 26;90(2):526-34
14735204
J Nutr. 2008 Dec;138(12):2323-7
19022952
J Clin Oncol. 2002 Sep 1;20(17):3617-27
12202662
Biochem Biophys Res Commun. 2008 Jan 25;365(4):801-7
18035049
Nat Rev Cancer. 2003 May;3(5):330-8
12724731
J Clin Oncol. 2001 May 1;19(9):2413-21
11331320
Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5860-5
14676107
Oncol Lett. 2010 Nov;1(6):973-980
22870097